Locations:
Search
Novel insights from a postmortem study combining imaging, pathology and clinical perspectives
Long-awaited efficacy against disability progression in nonrelapsing SPMS appears to be at hand
Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies
BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
No effect on symptom severity or disability, and low prevalence of long COVID
Using multidisciplinary care to address mood changes, mitigate daily stressors
MRI classifier identifies a subset of patients with disease marked by cortical atrophy, not demyelination
A co-author explains some of the key McDonald criteria revisions
The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial
Meaningful characterization is critical to advancing research and care, review authors contend
Advertisement
Advertisement